|
Publish Biotechnology Articles or Industry News
Biotech Professionals and Students - Share your knowledge - Get Recognition |
Home | Submit Articles | Login |
| ALL Categories | AGRICULTURE | CAREERS | GENETICS | HEALTHCARE | ISSUES | NEWS | STEM CELLS |
Need for Pediatric Formulations in Clinical Trials - Part IIBY: Preethi Venkateswaran | Category: Biotech Research | Submitted: 2011-06-17 21:45:35
PEDIATRIC CLINICAL TRIAL ANALYSIS There is a need for researchers to justify the reason as to why they are conducting the trials. The need of investigation should be weighed against the prevalence of the condition to be treated, the seriousness of the disease, the availability of alternative treatments, the uniqueness of the compound, the conditions seen in pediatrics, the age groups of children, safety concerns in pediatrics and finally the need for pediatric formulations. A brief overview of a few of these is being discussed below. Pediatric formulation Suitable pediatric formulation is still in demand by many practioners. The suitability includes palatability, appropriate strength and dose volume, favor and colors and route. Young children cannot swallow tablets, and liquids, suspensions, chewable tablets and suppositories may be needed for children of different age groups. The concentrations of licensed medications may be too high, necessitating further manipulation in the form of dilution with an excipient. The excipients in many liquid formulations may not be suitable for selected patient groups. For example, the propylene glycol content in amprenavir liquid formulation makes it unsuitable for children under the age of 4 to consume it. Severe delayed onset hypersensitivity reaction was associated with formulation of amoxicillin liquid; the reaction may have been caused by the exicipent. Hence manipulation with excipients should be focused as an important formulation aspect . Pharmacokinetic studies Pharmacokinetic studies are performed to support formulation developments and to determine pharmacokinetic parameters in different age groups to support dosing recommendations. They are generally conducted in children with a disease, which may lead to higher inter-individual variability than in adult health volunteers, although the data reflect clinical use better. Children are not usually subject to dose escalation studies similar to those carried out in adult populations. Data generation/collection becomes a main concern, hence the use of population pharmacokinetics and a sparse sampling approach is preferred which allow each patients to contribute as few as two to four observations at predetermined times to an overall population. Population pharmacokinetics seeks to discover which measurable pathophysiological factors cause changes in the dose-concentration relationship and to what degree, so that the appropriate dosage can be recommended. There is similar disease progression and response to dosage and the PK/PD relationship of the drug is similar between adults and children, only PK studies and Safety studies are suggested for dose determination. Efficacy studies For most of the drugs, efficacy studies are not carried out for children differently but just cut and copy pasted from adult data. Disodium pamidronate is licensed for use in Paget's disease and osteolytic lesions and bone pain in multiple myeloma and breast cancer in adults, but it has also been used in a variety of pediatric conditions, bone pain in Gaucher's disease, osteogenesis imperfecta, and malignant hypercalcaemia in childhood cancer. Therefore a number of efficacy studies for disodium pamidronate are required to ascertain the efficacy for the disease concerned. The differences in the pathology of the diseases may require different dosage and administration regimens. Safety studies Age-appropriate, normal laboratory values and clinical measurements should be used in adverse event reporting. Children with developing systems may respond differently to mature adults; some adverse events and drug interactions that occur in children may not be identified in adult studies. The effects of medicinal products on long-term growth and development may not be apparent, therefore long-term surveillance data may be needed to ascertain possible effects. Article Source: http://www.biotecharticles.com/ About Author / Additional Info: A Scientific Writer Comments on this article: (0 comments so far)
Additional Articles: • Some Genetic Manipulations of Phosphate Solubilizing Bacteria • Everyday Hazards in Biotechnology Lab. • Preparing Y3 Medium For Culturing Plants in Vitro • Plasma Membrane and Integral Membrane Proteins Latest Articles in "Biotech Research" category: • Human Longevity: A Revolution in Biotechnology and Nanotechnology. • Nanoparticles as Delivery Device For Gene Therapy • Biotechnology as a Tool in Medicine: Focus on Artemisinin • Tissue Cells and Skin Cells Reprogrammed Into Embryonic Stem Cells:- • Polymerase Chain Reaction (or PCR) - Technique For Amplifying DNA • Treatment of Heart Disease With Stem Cells • Biological Activities and Bioassays • DNA Sequencing: Maxam Gilbert Method • PCR Aspects and its Future | PCR versus Cloning • Plasmid as Vectors For Plant Transformation • Gene Isolation and Characterisation • Apoptosis and Cancer: A Review • Extraction of Nucleic Acids (DNA and RNA) From Plant Tissues • Stem Cells From Bone Marrow and Vein Leftovers Can Heal Damaged Hearts • Gene Transfer Techniques: Biolistics, Bacterial and Viral Transformation • Breast Cancer: Cactus For Womens Life • Mtt Assay: Assess The Viability Of Cell In Culture • Medicinal Plants: Source Of Medicine • Biotechnology Impact on Alzheimer's Disease Important Disclaimer: All articles on this website are for general information only and is not a professional or experts advice. We do not own any responsibility for correctness or authenticity of the information presented in this article, or any loss or injury resulting from it. We do not endorse these articles, we are neither affiliated with the authors of these articles nor responsible for their content. Please see our disclaimer section for complete terms. 
Copyright © 2010 biotecharticles.com - Do not copy articles from this website. |
|||||||
| | Home | Disclaimer | Xhtml | | |||||||
